- World rank, 2022–2025
- #21,034 of 28,054 · #32,575 all time
- Rank in United States
- #3,102 of 4,192
- Research works
- 191 ▲ 583% vs 2013–17
- Citations
- 1.8k 9.3 per fractional work
- Top-10% rate
- 11.0% record average 16.5%
- Open access
- 61% world 28%
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Economics, Econometrics and Finance, 3.9×. Every wedge is a field page.
- Economics, Econometrics and Finance 3.9×
- Immunology and Microbiology 3.1×
- Medicine 2.9×
- Mathematics 2.5×
- Decision Sciences 2.4×
- Pharmacology, Toxicology and Pharmaceutics 2.0×
- Neuroscience 1.9×
- Biochemistry, Genetics and Molecular Biology 1.6×
- Health Professions 1.5×
- Psychology 1.0×
- Dentistry 0.4×
- Nursing 0.4×
- Computer Science 0.4×
- Business, Management and Accounting 0.3×
- Energy 0.2×
- Agricultural and Biological Sciences 0.2×
- Social Sciences 0.1×
- Engineering 0.1×
- Environmental Science 0.0×
- Materials Science 0.0×
- Arts and Humanities 0.0×
Who are the top researchers at Syneos Health (United States)?
Ranked on the composite score, M.C. Dorst and E.E.A. van der Kuijl lead among researchers whose main affiliation is Syneos Health (United States).
- 1 M.C. Dorst United States · #1,385,072 worldwide 0 citations · 27 works
- 2 E.E.A. van der Kuijl United States · #1,430,947 worldwide 0 citations · 52 works
Which keywords describe research at Syneos Health (United States)?
By fractional works in 2022–2025, weighted toward what it does more of than the world: Epidemiology, Clinical Trials, Quality of Life, Precision Medicine, Prognostic Factors, Immunotherapy, Cost-effectiveness Analysis and Health Utility Measures.
- Therapeutic Targets
- Gene Therapy
- Recombinant Factor VIIa
- Immunogenicity
- Immunology
- Shareholder Value
- Rheumatoid Arthritis
- Financialization
- Adaptive Designs
- Monoclonal Antibodies
- Targeted Therapy
- Chimeric Antigen Receptor
- CAR T Cells
- Lymphoma
- Pathogenesis
- Health Utility Measures
- Prognostic Factors
- Chemotherapy
- Inflammation
- Clinical Trials
- Epidemiology
- Quality of Life
- Immunotherapy
- Precision Medicine
- Cost-effectiveness Analysis
- Biomarkers
- Inflammatory Bowel Disease
- Genetics
- Cancer Immunotherapy
- Clinical Outcomes
- Cardiovascular Risk
- Radiotherapy
- False Discovery Rate
- Predictive Modeling
- Rituximab
- Efficacy
- Genomics
- Prophylaxis
- Autoantibodies
- Glycemic Control
Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 40 words, with their numbers
- Epidemiology9▲ 2.6×35 topics
- Clinical Trials5▲ 9.0×13 topics
- Quality of Life5▲ 4.2×13 topics
- Inflammation4▲ 2.4×26 topics
- Immunotherapy4▲ 6.0×10 topics
- Chemotherapy3▲ 5.4×14 topics
- Precision Medicine3▲ 8.0×6 topics
- Prognostic Factors3▲ 8.6×8 topics
- Cost-effectiveness Analysis3▲ 43×1 topic
- Health Utility Measures3▲ 43×1 topic
- Biomarkers3▲ 5.1×6 topics
- Pathogenesis3▲ 6.8×7 topics
- Inflammatory Bowel Disease3▲ 29×4 topics
- Lymphoma3▲ 20×2 topics
- Genetics2▲ 4.0×8 topics
- CAR T Cells2▲ 36×1 topic
- Cancer Immunotherapy2▲ 18×2 topics
- Chimeric Antigen Receptor2▲ 36×1 topic
- Clinical Outcomes2▲ 12×3 topics
- Targeted Therapy2▲ 12×3 topics
- Cardiovascular Risk2▲ 8.1×5 topics
- Monoclonal Antibodies2▲ 28×2 topics
- Radiotherapy2▲ 6.2×7 topics
- Adaptive Designs2▲ 113×1 topic
- False Discovery Rate2▲ 113×1 topic
- Financialization2▲ 23×1 topic
- Predictive Modeling2▲ 8.5×2 topics
- Rheumatoid Arthritis2▲ 24×2 topics
- Rituximab2▲ 15×3 topics
- Shareholder Value2▲ 21×1 topic
- Efficacy2▲ 30×2 topics
- Immunology2▲ 20×2 topics
- Genomics2▲ 7.0×2 topics
- Immunogenicity2▲ 47×2 topics
- Prophylaxis2▲ 16×3 topics
- Recombinant Factor VIIa2▲ 47×2 topics
- Autoantibodies2▲ 8.2×4 topics
- Gene Therapy2▲ 9.9×3 topics
- Glycemic Control2▲ 12×4 topics
- Therapeutic Targets2▲ 12×2 topics
Which research topics does Syneos Health (United States) publish most on?
By volume in 2022–2025: Health Systems, Economic Evaluations, Quality of Life, CAR-T cell therapy research, Housing, Finance, and Neoliberalism and Statistical Methods in Clinical Trials.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Health Systems, Economic Evaluations, Quality of Life Economics and Econometrics 3 works
- 2 CAR-T cell therapy research Oncology 2 works
- 3 Housing, Finance, and Neoliberalism Finance 2 works
- 4 Statistical Methods in Clinical Trials Statistics and Probability 2 works
- 5 Biosimilars and Bioanalytical Methods Immunology 2 works
- 6 Inflammatory Bowel Disease Genetics 2 works
- 7 Chronic Lymphocytic Leukemia Research Genetics 2 works
- 8 Hemophilia Treatment and Research Hematology 2 works
- 9 Rheumatoid Arthritis Research and Therapies Rheumatology 1 works
- 10 Biomedical Ethics and Regulation Physiology 1 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Syneos Health (United States)'s research output changed?
Output in 2018–2022 was 583% higher than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Raleigh
- North Carolina State University
- PRA Health Sciences
- North Carolina Division of Public Health
- North Carolina Exploring Cultural Heritage Online
- NC Department of Health and Human Services
- Gad Consulting Services (United States)
- University of North Carolina System
- Meredith College
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.